rs12133641 — IL6R IL-6 receptor intronic variant

Deep intronic IL6R variant associated with atopic dermatitis risk and systemic IL-6 signaling, with the G allele elevating eczema risk while reducing inflammatory cardiovascular markers through altered IL-6 receptor expression or splicing

See your personal result for IL6R

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IL6R Intronic Variant — Where Atopic Risk Meets Cardiovascular Protection

The interleukin-6 receptor sits at one of the most versatile crossroads in human immunology. IL-6 is the cytokine that bridges innate and adaptive immunity, drives the acute-phase response (including C-reactive protein production), and modulates the balance between Th1-driven autoimmune inflammation and Th2-driven allergic disease. rs12133641 is an intronic variant11 intronic variant
Deep intronic variants (>100 bp from any exon) can act as cis-regulatory elements, affecting transcription factor binding, alternative splicing enhancers, or gene expression levels without changing the protein sequence itself located 1,226 bp downstream of an exon boundary in IL6R (c.1160+1226A>G), and it tags a regulatory haplotype with a striking bidirectional disease association: the G allele reduces systemic IL-6 signaling — lowering CRP and cardiovascular inflammation risk — while simultaneously elevating risk for atopic dermatitis and other Th2-mediated allergic conditions.

The Mechanism

IL6R encodes the membrane-bound alpha subunit of the IL-6 receptor22 IL-6 receptor
IL-6 signals through a two-component complex: IL6Rα (CD126, encoded by IL6R) binds IL-6 with low affinity, then recruits gp130 (IL6ST) to form the high-affinity signaling complex that activates JAK1/STAT3 pathways. A soluble form of IL6Rα (sIL-6R) is shed from the cell surface by ADAM10 and ADAM17 proteases; sIL-6R enables IL-6 trans-signaling33 trans-signaling
Trans-signaling allows IL-6 to activate cells that do not express membrane-bound IL6R, dramatically broadening IL-6's reach to endothelial cells, neurons, and other non-immune cell types on cells that lack membrane IL6R. rs12133641 lies in a deep intronic regulatory region and is in partial linkage disequilibrium with the coding variant rs2228145 (Asp358Ala, c.1073A>C), which reduces IL6R ectodomain shedding and lowers circulating sIL-6R levels. The intronic rs12133641 likely contributes independently to regulatory control of IL6R expression or alternative splicing.

The apparent paradox — reduced IL-6 signaling causing both cardiovascular protection and atopic risk — reflects IL-6's dual role in immune homeostasis. High systemic IL-6 signaling drives Th17 cell differentiation and pro-inflammatory CRP production (bad for heart disease); but IL-6 also suppresses Th2-type eosinophilic inflammation by promoting regulatory immune states. When IL6R variants dampen this suppressive arm, Th2 skewing and IgE-mediated atopic responses may increase.

The Evidence

The atopic dermatitis association was established in a large multi-ancestry GWAS meta-analysis44 large multi-ancestry GWAS meta-analysis
Budu-Aggrey et al., Nature Communications 2023; combining European, East Asian, Latin American, and African ancestry datasets with over 800,000 total participants published in Nature Communications (2023, n > 800,000 combined). The G allele was associated with increased AD risk at genome-wide significance (OR ~1.04, p=3×10⁻⁴⁵), an effect that is modest per-allele but highly replicated and consistent across ancestries.

The complementary cardiovascular signals confirm the variant's impact on systemic IL-6 tone. In CAD GWAS data55 CAD GWAS data
Hartiala et al. and CARDIoGRAMplusC4D consortium, combining 547,261 participants, the A allele (not G) associated with coronary artery disease risk (p=3×10⁻¹¹) — meaning the G allele is cardiovascular-protective. The most mechanistically direct signal is the CRP association66 CRP association
From large-scale CRP GWAS; the G allele consistently lowers CRP across multiple independent studies and populations: the G allele is one of the strongest CRP-reducing variants in the genome (β -0.116 log-units, p=4×10⁻⁴⁷). This confirms that rs12133641 genuinely modifies IL-6 trans-signaling output, not merely tags it.

In skin-specific immune responses, GWAS of mosquito bite reactions77 GWAS of mosquito bite reactions
Mitchell et al., PLOS Genetics 2017; 84,724 participants for bite size, 69,057 for itch intensity found the G allele associated with reduced itch intensity (β -0.021, p=9×10⁻⁹) and larger bite size (β +0.028, p=2×10⁻⁷) — consistent with a blunted IL-6-mediated acute inflammatory response to insect antigen, with compensatory Th2-driven wheal formation dominating instead.

Practical Implications

For GG homozygotes, the elevated atopic dermatitis risk is meaningful but modest on an absolute scale. AD affects ~15-20% of children and ~5-10% of adults at baseline; an OR of ~1.04 per allele translates to ~8% higher risk for GG versus AA, not a dramatic increase. The more actionable implication is recognizing the IL-6 signaling context when managing skin inflammation: GG carriers may respond differently to IL-6 pathway-targeting treatments, and the lower basal CRP may obscure inflammatory activity that would otherwise appear on standard inflammatory markers.

For AG heterozygotes — the most common genotype — the modest atopic risk elevation warrants awareness of AD triggers but not targeted intervention beyond standard skincare approaches specific to genetic barrier vulnerability.

Carriers of the G allele who are prescribed IL-6 receptor blockers (tocilizumab, sarilumab) for rheumatoid arthritis, giant cell arteritis, or cytokine release syndrome should be aware that rs12133641 status may influence baseline IL6R expression levels, potentially modifying therapeutic response magnitude.

Interactions

The coding variant rs2228145 (Asp358Ala, 1,313 bp upstream of rs12133641) is the most studied functional variant in IL6R and reduces IL6R ectodomain shedding. rs2228145 is the primary Mendelian randomization instrument for IL-6 signaling studies and has been used to model the effects of tocilizumab pharmacologically. rs12133641 and rs2228145 lie in the same gene and likely tag overlapping but not identical regulatory signals; the complete IL6R haplotype structure including both variants gives the most accurate representation of an individual's IL-6 receptor biology.

rs4129267 is another intronic IL6R variant at chr1:154,453,788 with similar population frequencies (~39% T allele in Europeans) that has been associated with CRP levels, asthma, and cardiovascular phenotypes — it may be in partial LD with rs12133641 and represent the same functional haplotype from a different tag position.

Drug Interactions

tocilizumab dose_adjustment literature
sarilumab dose_adjustment literature

Genotype Interpretations

What each possible genotype means for this variant.

AA Normal

Common reference genotype — typical IL-6 receptor tone and standard atopic dermatitis risk

You carry two copies of the A allele at rs12133641, the GRCh38 plus-strand reference genotype. This represents typical IL6R expression and signaling in the IL-6 pathway. About 32% of the global population shares this genotype. Your atopic dermatitis risk from this variant is at baseline, and your IL-6 trans-signaling capacity is standard. Note that the A allele is associated with somewhat higher CRP levels and modestly elevated coronary artery disease risk compared to G allele carriers — though the per-allele effect is small.

AG Intermediate

One copy of the G allele — mildly elevated atopic dermatitis risk, modestly lower IL-6 signaling

The G allele reduces IL-6 trans-signaling — the mechanism by which IL-6 signals on cells lacking membrane IL6R. This blunts the acute-phase CRP response and systemic IL-6 inflammatory tone. The flip side is that IL-6 also suppresses Th2-type immune skewing, so lower IL-6 signaling may allow IgE-mediated atopic responses to amplify more readily. For most AG carriers, this is a background risk factor rather than a clinically dominant signal — atopic dermatitis is a complex disease requiring multiple hits (FLG barrier gene variants, environmental exposures, microbiome disruption) to manifest.

GG High Risk

Two copies of the G allele — highest atopic dermatitis risk from this variant, reduced IL-6 inflammatory signaling

IL-6 normally acts to polarize naive T cells toward Th17 (pro-inflammatory) states and away from Th2 (allergic) states, in part through STAT3 activation that suppresses GATA3 expression. When IL6R variants reduce IL-6 receptor density or signaling efficiency, this Th17-promoting/Th2-suppressing signal weakens. The result is a micro-environment more permissive to IgE production, eosinophil recruitment, and the IL-4/IL-13/TSLP cytokine cascade that drives atopic dermatitis, allergic rhinitis, and asthma — the atopic march.

GG homozygotes may also notice that standard inflammatory markers like CRP are systematically lower than expected even during active inflammatory episodes. This does not mean inflammation is absent — alternative markers (serum amyloid A, fibrinogen, eosinophil count, IgE, IL-33) better reflect atopic inflammation than CRP in this genetic context.

The pharmacogenomic implication is also most pronounced in GG carriers: if prescribed anti-IL-6 receptor therapy (tocilizumab, sarilumab), GG carriers start from a lower baseline IL6R expression state, which could affect dose- response characteristics.